Abstract: A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.

Abstract: The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided.

Abstract: A mutated rhinovirus C, methods of creating and methods of propagating thereof, wherein the mutated rhinovirus shows enhanced virus yields after infection and induced visible cytopathic effect.

Abstract: The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided.

Abstract: The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided.

Abstract: A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.

Abstract: The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided.

Abstract: A mutated rhinovirus C, methods of creating and methods of propagating thereof, wherein the mutated rhinovirus shows enhanced virus yields after infection and induced visible cytopathic effect.

Abstract: The invention relates to compositions, specifically novel nucleic acid constructs encoding a cardiovirus 2A polypeptide operably linked to suitable promoters. Also, disclosed are methods whereby the nucleic acid constructs are introduced into cells or cell free systems to regulate cellular mRNA transcription and cap-dependent or internal ribosomal entry site (IRES)-dependent mRNA translation.

Abstract: Infection by human rhinovirus (HRV) causes upper and lower respiratory tract disease with varying degrees of virulence. The molecular basis of diversity was examined by completing the genome sequences for all known serotypes (n=99) as well as novel field samples. Superimposition of capsid crystal structure and optimal-energy RNA configurations established the alignments. The phylogeny revealed conserved motifs, Glade-specific diversity including a potential new species (clade-D), pan-genome mutations in field isolates, and unexpected recombination that contributes to heterogeneity. A spacer tract near a 5?-UTR cloverleaf was hypervariable, and in analogy with poliovirus, may be associated with virulence. A previously unidentified configuration consistent with non-scanning internal ribosome entry may account for rapid protein translation.

Abstract: A nucleic acid construct comprising at least two copies of a nucleic acid sequence encoding an autocatalytic peptide cleavage site is disclosed. This site preferably comprises the amino acid sequence DX(D,E)XNPGP. A method of exposing an animal to an antigenic amino acid sequence is also disclosed.

Abstract: A method for inhibiting picornavirus disease in non-murine mammals is disclosed. A vaccine containing a live, recombinant, attenuated picornavirus with a shortened poly(C) tract is administered to the mammal. Preferably, the picornavirus in the vaccine is of the same genus as the disease-causing picornavirus and has a shortened poly(C) tract. The administration of the vaccine causes antibodies effective against the disease-causing picornavirus to be formed in vivo. In one embodiment of the invention, a vaccine containing Mengovirus with a shortened poly(C) tract can be used as a vaccine for both pigs and monkeys.

Abstract: Disclosed in this patent are DNA sequences, RNA sequences, vectors, and hosts that incorporate a translation enhancer region derived from the 5' non-coding region of a cardiovirus. The enhancer acts at the RNA level (as opposed to the DNA level) to enhance production of proteins in cell free media. Proteinaceous material which is produced will not have attached to it any undesired material from the enhancer sequence. The invention is especially useful to enable efficient production of selected viral proteins of picornoviruses.